Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California. Show more
628 Middlefield Road, Palo Alto, CA, 94301, United States
Market Cap
162.1M
52 Wk Range
$2.14 - $12.90
Previous Close
$8.67
Open
$8.96
Volume
84,753
Day Range
$8.20 - $8.96
Enterprise Value
87.63M
Cash
77.0M
Avg Qtr Burn
-11.33M
Insider Ownership
10.28%
Institutional Own.
78.95%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
TH103 Details Neovascular Age-Related Macular Degeneration (nAMD) | Phase 1/2 Data readout |